5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release.
about
Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disordersPharmacology of hallucinations: several mechanisms for one single symptom?Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmissionF15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptorsThe effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label studyEffect of Pharmacological Interventions on the Fronto-Cingulo-Parietal Cognitive Control Network in Psychiatric Disorders: A Transdiagnostic Systematic Review of fMRI StudiesCan antipsychotics improve social cognition in patients with schizophrenia?Cognitive impairment in studies of 5HTTLPR and psychosis in Alzheimer's disease: a systematic reviewDopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptorsThe activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activityDopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and FutureAntipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotectionEffects of central activation of serotonin 5-HT2A/2C or dopamine D 2/3 receptors on the acute and repeated effects of clozapine in the conditioned avoidance response test.Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.Modulation of midbrain dopamine neurotransmission by serotonin, a versatile interaction between neurotransmitters and significance for antipsychotic drug action.F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors--a new analysis of data from the archives and implications for improved antimanic treatments.Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.Theranostic Biomarkers for SchizophreniaEffects of repeated risperidone exposure on serotonin receptor subtypes in developing rats.Neonatal 3,4-methylenedioxymethamphetamine (MDMA) exposure alters neuronal protein kinase A activity, serotonin and dopamine content, and [35S]GTPgammaS binding in adult rats.Treatment of the psychostimulant-sensitized animal model of schizophrenia.Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia.Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling.Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors.5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranes.Treatment with olanzapine is associated with modulation of the default mode network in patients with SchizophreniaThe neurochemistry of waking and sleeping mental activity: the disinhibition-dopamine hypothesis.Adjunctive treatment with asenapine augments the escitalopram-induced effects on monoaminergic outflow and glutamatergic neurotransmission in the medial prefrontal cortex of the ratAntidepressant prescribing patterns in Korea: results from the clinical research center for depression studyThe facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings.Effect of clozapine on interval timing and working memory for time in the peak-interval procedure with gaps.Novel antipsychotics in schizophrenia.The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes.
P2860
Q21129108-4AFB597F-B87D-4750-8C01-7EF3B18642C6Q21284720-8F1328D2-709B-45FD-9045-494D177940C2Q23913269-691C5748-7E90-4DD6-8A52-26CB157F57B7Q24564963-DC185177-082F-48D0-B755-009D24F91C36Q24672474-410B1EB1-1A6B-477F-B70B-1A098DCA3321Q24800019-15CAD44A-54B1-4C9E-809F-C2E37AA09173Q26744718-78BAE59A-CD26-4CFB-9A11-2BDD77E0BD95Q26822977-278B47B0-D01E-4CBD-B92F-A7BD0D3C9D6AQ26830556-1537B5AC-C002-42B5-9BCF-5BD0A3780459Q28273285-2704C55C-508F-4CC2-8900-A58114AAE4E5Q28281024-22E523F6-EC8B-47B7-9EF4-14911AF18536Q28394341-DBB5B439-8D89-4F07-BD9B-0524316B1609Q30386608-B0FFC932-D9E2-4D3D-9825-DE5189BA8825Q30387361-34792260-322C-4446-86AC-7683D324605AQ30493133-93235D95-27BD-47E7-8962-F2BD24B2F103Q30493995-AF9BFD3F-B6B4-439A-837F-4896D216BFBDQ30494674-F64E090A-9335-479F-8231-FE4A6FA96B09Q30524240-FA5FD571-5EF9-4670-9483-D8C46AEF91FBQ31163228-E4FC3BDC-0B0D-4FD9-98C9-CAD1CF4BBEBEQ33488312-116B16E1-E5A1-402E-93BB-61DF705A727CQ33624412-FBFDEF5E-D6CE-4E82-A47E-F46C05E7F7A6Q33643175-C7BE6D4B-301E-47F8-B94A-FF13E51D5E9AQ33923867-12217AE6-E7BE-4580-BCA7-C9AF37CE37D2Q34155012-A4CFBF91-C3BC-4A23-A1F8-CBB9CDA3B80DQ34169978-1D18D60F-5F76-4F61-8B1A-6F2EA943E03DQ34272454-EBF1322A-B4DB-4C99-90E3-EB69B397F018Q34311721-BEE19794-C576-48D5-972F-BC1202EE6271Q34338202-548D19A6-1552-497B-AAB3-018D7E35AA02Q34340909-B6E7F856-B6EF-4DB5-9D53-5C58B6B0D47EQ34350194-D34792DA-E1A2-49EB-9B05-0E373B1E439BQ34419652-99CB6AF7-2F44-4265-9031-0A0F9BA9DFDFQ34619843-2FAD24AC-B7D4-4F1D-BC62-8924C108749AQ34660641-AE46F129-DD61-43A1-A702-D901380C331BQ34730873-409051F3-3AF8-4B48-A64D-DF80C2B9A778Q35179053-3640BA12-EC27-4061-8AB4-65CF4447980BQ35238344-6B89DDF1-FA17-42A4-9B8B-57E779C69D59Q35369968-38B77857-D3C7-4E73-8EBF-C3577094975EQ35745220-9E4DA3EE-C541-4C8D-8272-5F8EFD72D1BBQ35753453-8FBEB948-6241-4735-9F5F-11E11D4C844AQ35860569-7B0FEFB6-BD98-4F2D-AC23-EAB62D2EFBAC
P2860
5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
5-HT(2A) and D(2) receptor blo ...... ced cortical dopamine release.
@ast
5-HT(2A) and D(2) receptor blo ...... ced cortical dopamine release.
@en
type
label
5-HT(2A) and D(2) receptor blo ...... ced cortical dopamine release.
@ast
5-HT(2A) and D(2) receptor blo ...... ced cortical dopamine release.
@en
prefLabel
5-HT(2A) and D(2) receptor blo ...... ced cortical dopamine release.
@ast
5-HT(2A) and D(2) receptor blo ...... ced cortical dopamine release.
@en
P2093
P2860
P1476
5-HT(2A) and D(2) receptor blo ...... ced cortical dopamine release.
@en
P2093
H Y Meltzer
I A O'Laughlin
J Ichikawa
S Bonaccorso
W L Fowler
P2860
P304
P356
10.1046/J.1471-4159.2001.00154.X
P407
P577
2001-03-01T00:00:00Z